# Pfizer Inc: insider transactions

SEC CIK 78003. Roles and transactions as reported on Form 4. Latest Form 4 filed 2020-12-22.

## Roles

| Company | Role | Transactions | First | Latest |
| --- | --- | ---: | --- | --- |
| [BioAtla, Inc.](/companies/bcab.md) | 10% owner | 2 | 2020-12-18 | 2020-12-18 |
| [Viatris Inc](/companies/vtrs.md) | 10% owner | 2 | 2020-11-13 | 2020-11-16 |
| [Enliven Therapeutics, Inc.](/companies/elvn.md) | 10% owner | 7 | 2020-03-16 | 2020-03-16 |
| [Allogene Therapeutics, Inc.](/companies/allo.md) | 10% owner | 3 | 2018-10-15 | 2018-10-15 |

## Transactions: 14

Every transaction reported, newest first. Codes P and S are open-market purchases and sales. Reported price is as stated on the form.

| Date | Company | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | ---: | ---: | ---: | --- |
| 2020-12-18 | [BioAtla, Inc.](/companies/bcab.md) | Conversion (C), derivative | 2,238,090 | not reported | not reported | [Form 4](/filings/0000078003-20-000080.md) |
| 2020-12-18 | [BioAtla, Inc.](/companies/bcab.md) | Conversion (C) | 2,238,090 | not reported | not reported | [Form 4](/filings/0000078003-20-000080.md) |
| 2020-11-16 | [Viatris Inc](/companies/vtrs.md) | Other (J) | 689,874,047 | $0.00 | $0 | [Form 4](/filings/0000899243-20-031144.md) |
| 2020-11-13 | [Viatris Inc](/companies/vtrs.md) | Other (J) | 689,873,947 | $0.00 | $0 | [Form 4](/filings/0000899243-20-031144.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Conversion (C), derivative | 1,894,444 | $0.00 | $0 | [Form 4](/filings/0000078003-20-000023.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Conversion (C), derivative | 5,470,492 | $0.00 | $0 | [Form 4](/filings/0000078003-20-000023.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Conversion (C), derivative | 478,749 | $0.00 | $0 | [Form 4](/filings/0000078003-20-000023.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Purchase (P) | 312,500 | $16.00 | $5.0m | [Form 4](/filings/0000078003-20-000023.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Conversion (C) | 300,752 | not reported | not reported | [Form 4](/filings/0000078003-20-000023.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Conversion (C) | 868,467 | not reported | not reported | [Form 4](/filings/0000078003-20-000023.md) |
| 2020-03-16 | [Enliven Therapeutics, Inc.](/companies/elvn.md) | Conversion (C) | 76,003 | not reported | not reported | [Form 4](/filings/0000078003-20-000023.md) |
| 2018-10-15 | [Allogene Therapeutics, Inc.](/companies/allo.md) | Conversion (C), derivative | 4,185,997 | $0.00 | $0 | [Form 4](/filings/0000078003-18-000080.md) |
| 2018-10-15 | [Allogene Therapeutics, Inc.](/companies/allo.md) | Purchase (P) | 55,556 | $18.00 | $1.0m | [Form 4](/filings/0000078003-18-000080.md) |
| 2018-10-15 | [Allogene Therapeutics, Inc.](/companies/allo.md) | Conversion (C) | 21,976,484 | not reported | not reported | [Form 4](/filings/0000078003-18-000080.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 08:28 ET. No prices; not investment advice.